Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis
Authors:
- Maibritt NørgaardMNMaibritt Nørgaard
- Christa HaldrupCHChrista Haldrup
- Tine Maj StorebjergTSTine Maj Storebjerg
- Else Marie VestergaardEVElse Marie Vestergaard
- Peter J. WildPWPeter J. Wild
- Søren HøyerSHSøren Høyer
- Michael BorreMBMichael Borre
- Torben Falck ØrntoftTØTorben Falck Ørntoft
- Karina Dalsgaard SørensenKSKarina Dalsgaard Sørensen
Open Access
- 20 September 2017
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 18 (9) , 2017
Abstract
Overdiagnosis and overtreatment of clinically insignificant tumors remains a major problem in prostate cancer (PC) due to suboptimal diagnostic and prognostic tools. Thus, novel biomarkers are urgently needed. In this study, we investigated the biomarker potential of Trefoil factor 3 (TFF3) promoter methylation and RNA expression levels for PC. Initially, by quantitative methylation specific PCR (qMSP) analysis of a large radical prostatectomy (RP) cohort (n = 292), we found that the TFF3 promoter was significantly hypomethylated in PC compared to non-malignant (NM) prostate tissue samples (p < 0.001) with an AUC (area under the curve) of 0.908 by receiver operating characteristics (ROC) curve analysis. Moreover, significant TFF3 promoter hypomethylation (p ≤ 0.010) as well as overexpression (p < 0.001) was found in PC samples from another large independent patient sample set (498 PC vs. 67 NM) analyzed by Illumina 450K DNA methylation arrays and/or RNA sequencing. TFF3 promoter methylation and transcriptional expression levels were inversely correlated, suggesting that epigenetic mechanisms contribute to the regulation of gene activity. Furthermore, low TFF3 expression was significantly associated with high ERG, ETS transcription factor (ERG) expression (p < 0.001), as well as with high Gleason score (p < 0.001), advanced pathological T-stage (p < 0.001), and prostate-specific antigen (PSA) recurrence after RP (p = 0.013; univariate Cox regression analysis). There were no significant associations between TFF3 promoter methylation levels, ERG status, or PSA recurrence in these RP cohorts. In conclusion, our results demonstrated diagnostic biomarker potential of TFF3 promoter hypomethylation for PC as well as prognostic biomarker potential of TFF3 RNA expression. To the best of our knowledge, this is the most comprehensive study of TFF3 promoter methylation and transcriptional expression in PC to date.Keywords
Funding Information
- Kræftens Bekæmpelse
- Innovationsfonden
- The Danish Agency for Science Technology and Innovation
This publication has 63 references indexed in Scilit:
- DNA Methylation Signatures for Prediction of Biochemical Recurrence After Radical Prostatectomy of Clinically Localized Prostate CancerJournal of Clinical Oncology, 2013
- Tissue of origin determines cancer-associated CpG island promoter hypermethylation patternsGenome Biology, 2012
- Functions of DNA methylation: islands, start sites, gene bodies and beyondNature Reviews Genetics, 2012
- Evaluation of the Infinium Methylation 450K technologyEpigenomics, 2011
- Integrative Genomic Profiling of Human Prostate CancerCancer Cell, 2010
- Development of a Diagnostic Microarray Assay to Assess the Risk of Recurrence of Prostate Cancer Based on PITX2 DNA MethylationThe Journal of Molecular Diagnostics, 2010
- TopHat: discovering splice junctions with RNA-SeqBioinformatics, 2009
- Ultrafast and memory-efficient alignment of short DNA sequences to the human genomeGenome Biology, 2009
- Prospective diagnostic efficiency of biopsy washing DNA GSTP1 island hypermethylation for detection of adenocarcinoma of the prostateThe Prostate, 2007
- Pathological features of prostate cancer detected on initial and repeat prostate biopsy: Results of the prospective European prostate cancer detection studyThe Prostate, 2001